A Small Molecule Agonist of an Integrin, αLβ2*S

Wei Yang‡,§,1, Christopher V. Carman‡,§,1, Minsoo Kim‡,¶,2, Azucena Salas‡,§,¶,3, Motomu Shimaoka‡,¶, and Timothy A. Springer‡,§,1
‡ From the CBR Institute for Biomedical Research, Departments of
§ Pathology and
¶ Anesthesia, Harvard Medical School, Boston, Massachusetts 02115

Abstract

The binding of integrin αLβ2 to its ligand intercellular adhesion molecule-1 is required for immune responses and leukocyte trafficking. Small molecule antagonists of αLβ2 are under intense investigation as potential anti-inflammatory drugs. We describe for the first time a small molecule integrin agonist. A previously described α/βI allosteric inhibitor, compound 4, functions as an agonist of αLβ2 in Ca2+ and Mg2+ and as an antagonist in Mn2+. We have characterized the mechanism of activation and its competitive and noncompetitive inhibition by different compounds. Although it stimulates ligand binding, compound 4 nonetheless inhibits lymphocyte transendothelial migration. Agonism by compound 4 results in accumulation of αLβ2 in the uropod, extreme uropod elongation, and defective de-adhesion. Small molecule integrin agonists open up novel therapeutic possibilities.

Integrins are a large family of α/β heterodimeric cell surface receptors that mediate cell-cell and cell-extracellular matrix adhesion and transduce signals bidirectionally across the plasma membrane. Integrin αLβ2 (lymphocyte function associated antigen-1 (LFA-1))5 belongs to the β2 integrin subfamily and is constitutively expressed on all leukocytes. αLβ2 remains in a low affinity state in resting lymphocytes and undergoes dramatic conformational change during lymphocyte activation, which greatly increases its binding affinity for its ligands intercellular adhesion molecule-1, -2, and -3 (ICAM-1, -2, and -3). Regulation of αLβ2 activation is pivotal for controlling leukocyte trafficking and immune responses in health and diseases (1–3).

αLβ2 is an important pharmaceutical target for treating autoimmune and inflammatory diseases (4–8). A humanized anti-body to αLβ2 that blocks its binding to the ligand ICAM-1 has been approved by the FDA for treatment of psoriasis, a T cell-mediated autoimmune disease of the skin (9, 10). Furthermore, small molecule antagonists of αLβ2 have been discovered and are in development (11–17).
αLβ2 contains two von Willebrand factor-type A domains, the inserted (I) domains in the αL and the β2 subunits (18–20). Both αL I and β2 I domains have a Rossman fold (i.e. a central β-sheet surrounded by α-helices) with a metal ion-dependent adhesion site (MIDAS) formed by β-α-loops at the “top” face of the domain (20–23). In ligand binding the Mg2+ ion in the MIDAS of the αL I domain coordinates directly to a Glu residue that is in the center of the ligand binding sites in domain 1 of ICAM-1 and ICAM-3 (20, 24). The affinity of the αL I domain for ICAMs is regulated by downward axial displacement of its C-terminal α7 helix, which is conformationally linked to reshaping of MIDAS loops and increases affinity for ligand by up to 10,000-fold (25, 26). During activation, the βI domain undergoes similar α7 helix downward axial movement, which is induced by the swing out of the hybrid domain (27–30).

Previous data suggested that when activated, the β2 I domain binds (through the Mg2+ in its MIDAS) to the Glu residue (Glu-310) in the C-terminal linker of the αL I domain, exerts a downward pull on its α7 helix, and thereby activates the αL I domain (Fig. 1A) (32, 33).

Two distinct classes of small molecule antagonists of αLβ2 have been developed as anti-inflammatory agents. One group of antagonists binds the hydrophobic pocket underneath the α7 helix of the αL I domain (e.g. LFA703 or BIRT377), blocks the downward axial movement of the α7 helix, and inhibits ligand binding of αLβ2 allosterically by stabilizing the αL I domain in the low affinity conformation (11–14, 34). These antagonists are called αI allosteric inhibitors. The other group of antagonists appears to bind to the β2 I domain MIDAS near a key regulatory interface with the αL I domain, blocking communication of conformational change to the αL I domain while at the same time activating conformational rearrangements elsewhere in integrins (35–37). These antagonists, such as compounds 3 and 4 from Genentech and XVA143 from Hoffmann-La Roche, are called α/βI allosteric inhibitors (Fig. 1B). In this report, however, we describe that compound 4, previously regarded as an α/βI allosteric inhibitor based on studies in Mn2+, actually activates αLβ2 under physiological conditions in Ca2+, and Mg2+ and inhibits integrin-dependent functions by perturbing de-adhesion.

**EXPERIMENTAL PROCEDURES**

**Antibodies and Small Molecule Inhibitors**

mAbs to human αL and β2 are as described (34). m24 (38) and KIM127 (39) were kind gifts of N. Hogg (London Research Institute) and M. Robinson (Celltech, Slough, UK), respectively. Compound 5 (XVA143) was synthesized according to example 345 of the patent (35) and was also obtained from P. Gillespie (Hoffmann-La Roche). Compounds 3 and 4 were obtained from Genentech (South San Francisco, CA) through the research reagents program. LFA703 (11, 12) was provided by Novartis Pharma AG (Basel, Switzerland), and BIRT377 was from T. Kelly (Boehringer Ingelheim Pharmaceuticals Inc, Ridgeway, CT).

**Cell Isolation and Culture**

K562 transfectants expressing wild-type and mutant αLβ2 were described (40). Preparation of human peripheral blood mononuclear cells (PBMCs) and interleukin-2-cultured primary lymphocytes was previously described (41). Primary human umbilical vein endothelial cells (HUVECs) were from Cambrex (Walkersville, MD) and cultured as confluent monolayers on fibronectin (10 μg/ml) coated on glass coverslips or ΔT live-cell imaging chambers (Bioptechs, Butler, PA) in EGM-2 complete media (Cambrex, Walkersville, MD).

---

6Nishida, N., Xie, C., Shimaoka, M., Cheng, Y., Walz, T., and Springer, T. A., (2006) *Immunity* 25, 583–594.
Binding of Soluble ICAM-1

Binding of soluble ICAM-1-IgA Fc fusion protein complexed with affinity-purified, fluorescein isothiocyanate-conjugated anti-human IgA was measured by flow cytometry (37).

Cell Adhesion to Immobilized ICAM-1

Binding of fluorescently labeled transfectants to immobilized ICAM-1 was as described (40). Briefly, ICAM-1-IgG Fc fusion protein at 10 μg/ml was immobilized on microtiter plates previously coated with 20 μg/ml protein A and blocked with 2% human serum albumin. Binding of transfectants to immobilized ICAM-1 was determined in Hepes, NaCl, glucose, bovine serum albumin (BSA; 20 mM Hepes, pH 7.5, 140 mM NaCl, 2 mg/ml glucose, 1% BSA) supplemented with divalent cations and compounds as indicated. After incubation at 37 °C for 30 min, unbound cells were washed off, and bound cells were quantitated (40).

Flow Chamber Assay

Binding and detachment in shear flow of αLβ2 transfectants on immobilized ICAM-1 substrates was done in a parallel plate flow chamber as described (42).

Fluorescence Resonance Energy Transfer (FRET) Assay

FRET assay using αL-monomeric cyan fluorescent protein (mCFP)/β2-monomeric yellow fluorescent protein (mYFP) K562 stable transfectants was as described (43).

Cell Migration Assays

Lymphocyte transendothelial migration assays were as described (41). Briefly, before each experiment confluent HUVEC monolayers were activated for 12 h with TNF-α(100 ng/ml). HUVECs were then washed 3 times in buffer A (Hanks’ balanced salt solution supplemented with 20 mM Hepes, pH 7.2, and 1% human serum albumin). Interleukin 2-cultured primary human lymphocytes were pelleted, resuspended at 100,000 cells/ml in 500 μl of buffer A containing compound 4 (1 μM), compound 5 (1 μM), BIRT737 (20 μM), or CBR LFA-1/2 Fab (20 μg/ml) and then added to HUVECs and incubated at 37 °C for 10 or 60 min. Samples were fixed in 3.7% formaldehyde in phosphate-buffered saline for 5 min and stained for leukocyte αL integrin (TS2/4 mAb conjugated to Cy3), endothelial cell ICAM-1 (IC1/11 mAb conjugated to Alexa488), and F-actin (phallolidin-Alexa647; Molecular Probes) as described (41). Imaging was conducted using Bio-Rad Radiance 2000 Laser-scanning confocal microscope system. For each condition complete Z-stacks (0.5 μM thickness) were obtained in each of ten randomly selected fields. Using LaserSharp 2000 software (Bio-Rad) Z-stacks were analyzed (based on previously described criteria (41)) to determine the number of cells in the process of, or having completed diapedesis.

Morphological analysis of the apically adherent lymphocyte population was based both on the overall cell shape and the distribution of actin and αLβ2. Cells exhibiting generally even actin and αLβ2 distributions and either spherical or symmetrically spread shapes were designated as “round” or “spread”, respectively. Cells exhibiting polarized shapes with an actin-enriched leading edge and roughly even distribution of LFA-1 were designated “polarized”. Cells that exhibited both extended uropods and sequestration of the majority of the cellular LFA-1 to the uropod were designated as “X-polarized” (i.e. extremely polarized).

For live-cell experiments confluent TNF-α-activated HUVEC monolayers were prepared on Bioptechs ΔT imaging chambers, rinsed three times with buffer A, and maintained at 37 °C. Lymphocytes (100,000) were added to the chambers, and differential interference contrast images were acquired (using a Zeiss Axiovert S200 epifluorescence microscope (Germany) equipped with a 63× oil objective coupled to a Hamamatsu Orca CCD (Japan)) at 5-s intervals.
over a course of 30 min. Cell migration was analyzed by manually tracing the outline of each cell in selected frames (i.e. at 180-s intervals) for each time course. Lines connecting the centroid of each cell outline (automatically calculated by OpenLab software) were generated to represent the migration path or “track” followed by each lymphocyte. The total length of the cell tracks was divided by the total time interval during which the track was recorded to calculate average migration velocity. The linear distance between the beginning and endpoint of each track was measured to determine the overall displacement of each cell. Measurement of cell lateral migration parameters was restricted to lymphocytes during their migration over the apical surface of the endothelium and discontinued upon diapedesis across the endothelial monolayer to the subendothelial space. The percentage of diapedesis was obtained by dividing the number of cells that initiated diapedesis by the total number of migrating cells.

To analyze the qualitative details of migration behavior, representative cells were traced at 50-s intervals. The distance separating the centroid of the cell in the initial frame and the centroid of the cell at each subsequent interval was plotted against the cumulative time elapsed.

Online Supplemental Material

Supplemental Videos 1 and 2 are representative videos of lymphocyte migration in the absence (Video 1) and presence (Video 2) of compound 4 as described in Figs. 7, C and D, respectively.

RESULTS

Compound 4 Activates αLβ2 in Physiologic Cations (Ca2+/Mg2+) but Inhibits in Mn2+

K562 cells expressing αLβ2 showed little binding to soluble multimeric ICAM-1 in Ca2+/Mg2+ (Fig. 2A), whereas binding was greatly increased by Mn2+ (Fig. 2B) or the activating mAb CBR LFA-1/2 (Fig. 2C). In Mn2+, compounds 3–5 potently inhibited soluble, multimeric ICAM-1 binding by αLβ2 (Fig. 2B), consistent with previous observations (17, 37). However, in physiologic cations (i.e. 1 mM Ca2+ and 1 mM Mg2+) we found, unexpectedly, that compound 4 greatly increased ligand binding, whereas compounds 3 and 5 had no effect (Fig. 2A). Furthermore, activation of αLβ2 binding to ICAM-1 in Ca2+/Mg2+ by CBR LFA-1/2 mAb was further increased by compound 4 but inhibited by compounds 3 and 5 (Fig. 2C).

Next we assessed the effects of these compounds on physiologic leukocytes (i.e. primary human PBMCs). The PBMCs showed weak binding to soluble multimeric ICAM-1 in Ca2+/Mg2+ alone and significant binding in Mn2+ alone (Fig. 2D). Consistent with our observations with K562 transfectants (Fig. 2, A–C), compound 4 strongly increased binding of soluble ICAM-1 to PBMCs in Ca2+/Mg2+ but inhibited Mn2+-induced binding (Fig. 2D). Both compound 4- and Mn2+-induced ICAM-1 binding was αLβ2-dependent, as such binding was completely inhibited by the αL I domain-specific blocking anti-body TS2/14 (Fig. 2D).

The activating effect of compound 4 was confirmed and further analyzed using static cell adhesion and flow chamber assays. In the static cell adhesion assay, K562 cells expressing αLβ2 were allowed to adhere to immobilized ICAM-1, and the unbound cells were removed with an automatic plate washer. In the presence of Ca2+/Mg2+ alone very little cell adhesion was observed, whereas in the presence of Mn2+ alone adhesion was greatly enhanced (Fig. 2E). The addition of either compound 4 or 5 abolished Mn2+-induced adhesion. In contrast, in Ca2+/Mg2+ compound 4, but not compound 5, greatly increased cell adhesion (Fig. 2E). In a flow chamber assay, K562 cells expressing αLβ2 showed weak rolling and firm adhesion to immobilized ICAM-1 in Ca2+/Mg2+ (Fig. 2F). As demonstrated previously, the addition of compound 5 in Ca2+/Mg2+ significantly increased rolling adhesion, and Mn2+ increased firm adhesion (42). At a shear stress of 2 dyn/cm2, compound 4 in Ca2+/Mg2+ induced firm adhesion to a similar extent as observed with Mn2+ alone. Under a high shear regime of 32 dyn/cm2...
compound 4 still promoted significant adhesion (Fig. 2F). However, the total number of rolling and firmly adherent cells was reduced by about half, whereas the amount of adhesion in Mn$^{2+}$ alone remained essentially unchanged. Thus, $\alpha_I\beta_2$ adhesiveness induced by compound 4 is less shear-resistant than adhesiveness induced by Mn$^{2+}$.

The Activating Effect of Compound 4 Is Inhibited by Compound 5 Competitively

—Compound 4 and compound 5 have homologous structures, and our previous findings suggested that both compounds bind to the MIDAS of the $\beta_2$ I domain (37). However, in Ca$^{2+}$/Mg$^{2+}$, compound 4 was activating, whereas compound 5 was inhibitory to wild type $\alpha_I\beta_2$ (Fig. 2). Therefore, we studied whether ICAM-1 binding to $\alpha_I\beta_2$ in Ca$^{2+}$/Mg$^{2+}$ stimulated by compound 4 could be competitively inhibited by compound 5. We found that $\alpha_I\beta_2$ activation by 50 nM compound 4 was reversed by compound 5 in a dose-dependent manner (Fig. 3A). Importantly, the inhibitory dose-response curve of compound 5 was shifted significantly to the right in the presence of a higher concentration (1 $\mu$M) of compound 4 (Fig. 3A). Such concentration dependence demonstrates a competitive mode of inhibition. Binding to ICAM-1 stimulated by compound 4 was also inhibited by an $\beta$I allosteric inhibitor, LFA703, that binds the hydrophobic pocket underneath the $\alpha_7$ helix of the $\alpha_I$ domain (Fig. 3B). However, the inhibitory dose-response curve of LFA703 was identical with 50 and 1000 nM compound 4, demonstrating non-competitive inhibition.

Compound 4 and Mn$^{2+}$ Activate $\alpha_I\beta_2$ by Different Mechanisms——The interaction between the $\beta_2$ MIDAS and an acidic residue in the C-terminal linker of $\alpha$ I domains, e.g. Glu-310 in $\alpha_I$, is indispensable for Mn$^{2+}$-induced activation of $\beta_2$ integrins (32, 33, 44). Mutation of either the metal-coordinating MIDAS residue Ser-114 in the $\beta_2$ I domain or Glu-310 in the $\alpha_I$ domain C-terminal linker totally abolished Mn$^{2+}$-induced ICAM-1 binding (Fig. 4). Mutation of another nearby acidic residue in the C-terminal linker of the $\alpha_I$ domain, $\alpha_I$-E316, only partially reduced Mn$^{2+}$-induced ligand binding and served as a control (Fig. 4). Consistent with our previous conclusion that compound 4 binds to the MIDAS of the $\beta_2$ I domain (37), the $\beta_2$ Ser-114 mutation completely abolished both inhibition of ICAM-1 binding in Mn$^{2+}$ by compound 4 and stimulation of ICAM-1 binding in Ca$^{2+}$/Mg$^{2+}$ by compound 4 (Fig. 4). Despite the absolute requirement for $\alpha_I$-Glu-310 in Mn$^{2+}$-induced ICAM-1 binding by $\alpha_I\beta_2$, compound 4 was able to activate binding to ICAM-1 by the $\alpha_I$-E310A mutant, demonstrating that compound 4 activates $\alpha_I\beta_2$ by a mechanism that is distinct from that of Mn$^{2+}$.

Susceptibility to $\alpha_I\beta_2$ Inhibitory Antibodies——mAbs exist that inhibit $\alpha_I\beta_2$ function by distinct mechanisms. Whereas some mAbs bind to the $\alpha_I$ I domain and competitively block ICAM-1 binding, other $\alpha_I$ I domain and $\beta_2$ I domain mAbs block ICAM-1 binding indirectly through allosteric mechanisms (34, 45, 46). We compared inhibition by a panel of these mAbs of CBR LFA-1/2-activated $\alpha_I\beta_2$ (wild type + mAb); $\alpha_I$-Glu-310C/$\beta_2$-A210C (CC), an $\alpha_I\beta_2$ mutant that is constitutively activated by introducing an intersubunit disulfide bond between residue 210 in a $\beta_2$ I domain MIDAS loop and the $\alpha_I$-Glu-310 residue (33); $\alpha_I\beta_2$ activated by compound 4 in Ca$^{2+}$/Mg$^{2+}$ (wild type + #4); and $\alpha_I\beta_2$ activated by a disulfide bond mutationally introduced into the $\alpha_I$ domain (HA) (Table 1). The $\alpha_I$-E310C/$\beta_2$-A210C mutant and wild-type $\alpha_I\beta_2$ activated by compound 4 showed almost identical susceptibility, i.e. they were inhibited by both the competitive $\alpha_I$ domain mAbs and the allosteric TS2/14 $\alpha_I$ domain mAb, were partially inhibited by mAb to Glu-175 in the specificity-determining loop of the $\beta_2$ I domain, and were resistant to mAbs to residues in the $\alpha_1$ helix (133) and $\alpha_7$ helix (332 and 339) of the $\beta_2$ I domain.

Effect of Compounds on $\alpha_I\beta_2$ Conformation——mAbs m24 and KIM127 represent reporters for $\alpha_I\beta_2$ active conformations. Whereas m24 recognizes the active conformation of
the β2 I domain, KIM127 binds to an epitope in the β2 EGF2 domain that is buried in the bent (i.e. latent) integrin conformation and exposed in the extended (i.e. active) conformation. Compounds 3–5 induced exposure of the m24 and KIM127 epitopes on cell surface αLβ2 with similar dose responses (Fig. 5A and B), in agreement with previous measurements on purified αLβ2 with compounds 4 and 5 (37).

We previously developed a FRET method to monitor the spatial proximity of αL and β2 cytoplasmic domains in living cells by fusing mCFP and mYFP to the C termini of αL and β2, respectively (43). Efficient FRET can only be observed when the cytoplasmic tails of αL and β2 (and, therefore, the fused mCFP and mYFP) are in close proximity. Consistent with our previous observations (43), we found here that stable K562 cell transfectants expressing αL-mCFP/β2-mYFP exhibited a significant FRET signal under basal conditions and that FRET was significantly decreased by treatment with Mn2+ plus soluble monomeric ICAM-1 (Fig. 5C). Exposure to either compound 4 or 5 in Ca2+/Mg2+ also statistically significantly reduced FRET, although to a somewhat lesser extent. These data suggest that compounds 4 and 5, consistent with induction of exposure of the m24 and KIM127 epitopes (Fig. 5, A and B), induce spatial separation of the αL and β2 cytoplasmic domains (Fig. 5C).

Compounds 4 and 5 Inhibit Lymphocyte Transendothelial Migration by Distinct Mechanisms——To assess the effects of compounds on transendothelial migration, i.e. diapedesis, we monitored migration of interleukin-2-cultured primary human lymphocytes through TNF-α-activated HUVEC monolayers in medium with Ca2+/Mg2+ by confocal microscopy. Under control conditions, efficient lymphocyte transendothelial migration was observed (~45% by 10 min and ~70% by 60 min). Compared with control, compound 4, compound 5, and BIRT377, an βI allosteric antagonist (Fig. 6A), all inhibited transendothelial migration by greater than 2-fold. Interestingly, Fab fragments of the αLβ2-activating antibody, CBR LFA-1/2, also produced a comparable inhibition of diapedesis (Fig. 6A).

Despite similarity in overall extent of inhibition of diapedesis, morphological analysis (as described under “Experimental Procedures”) revealed dramatic differences among these antagonists (Fig. 6, B–D). Under control conditions (Me2SO), the majority of the cells were polarized, whereas the remaining cells were equally divided into round and spread populations. In the presence of either compound 5 or BIRT377, the polarized cell population was reduced by greater than 2-fold, and the round cell population was dominant (Fig. 6, C and D). In stark contrast, for both compound 4 and CBR LFA-1/2 Fab treatments, the major cell population was in an unphysiologic “extremely polarized” (X-polarized) state in which the uropod was extended in length and dramatically enriched in αLβ2, concomitant with depletion of αLβ2 from other regions of the cell (Fig. 6, B–D).

The findings that compound 4 and CBR-LFA1/2 activate adhesiveness and induce extreme polarization and localization of LFA-1 to the uropod suggest that they may suppress lymphocyte migration by preventing de-adhesion of the uropod. To test the hypothesis that compound 4 inhibits migration, we performed live-cell imaging of lymphocytes migrating on endothelial monolayers (Fig. 7 and supplemental Videos 1 and 2). Quantitative analysis of more than 50 lymphocytes revealed a greater than 2-fold reduction by compound 4 in both average lateral migration velocity and in the mean displacement of the lymphocytes and a nearly 3-fold reduction in the frequency of diapedesis (Fig. 7, A and B). Analysis of the live-cell imaging demonstrates that, in contrast to the relatively steady and smooth migration observed under control conditions (Fig. 7, C and E, and Video 1), compound 4 promotes “jerky” or “frustrated” migration in which the leading edge and cell body repeatedly advance, then become partially retracted back toward the uropod (Fig. 7, D–E, and Video 2).
DISCUSSION

The interaction between αLβ2 and ICAM-1 plays a critical role in the formation of the immunological synapse in immune responses and in leukocyte adhesion and extravasation through endothelium. αLβ2 is a clinically validated target for the treatment of autoimmune disease, and small molecule antagonists of αLβ2 are under intense investigation. Here, we show that a class of compounds previously classified as α/β allosteric antagonists includes among its members a compound that is an agonist of αLβ2 in the presence of physiologic divalent cations, i.e. Ca^{2+} and Mg^{2+}. In contrast, compound 4 is an antagonist in Mn^{2+}, as previously reported (17, 37). Agonism in Ca^{2+}/Mg^{2+} and antagonism in Mn^{2+} was consistently observed in soluble multimeric ICAM-1 binding assays, static cell adhesion, and flow chamber assays and with both K562 transfecants expressing αLβ2 and physiologic leukocytes, i.e. PBMCs. In parallel assays the structurally homologous compounds 3 and 5 (XVA143) exhibit only antagonistic properties. The finding that compound 4 can act as both an agonist and antagonist support our previous conclusion that it is an allosteric effector (37) and does not mimic and directly compete binding of ICAM-1 (17, 47).

Compounds 3–5 (XVA143) have very similar structures and appear to have overlapping binding sites. The ability of all three compounds to stabilize non-covalent association of the αL and β2 subunits in SDS-PAGE is not dependent on the αL I domain and is absolutely dependent on divalent cations and the β2 I domain MIDAS residue Ser-114. Mn^{2+} and Ca^{2+}/Mg^{2+} each support stabilization of αLβ2 and αMβ2 noncovalent complexes in SDS-PAGE. All three compounds inhibit ligand binding by αLβ2 as well as αLβ2 (37). Antagonism and agonism by compound 4 appear to occur at the same binding site, since the closely related compound 5 competitively antagonizes agonism by compound 4, and agonism requires β2 I domain residue Ser-114.

The mechanism of αL I domain activation by compound 4 differs somewhat from mechanisms previously described for other αL I domain activators. For αLβ2 stimulated with either Mn^{2+} or CBR LFA-1/2, mutation of Glu-310 to Ala at the C-terminal αL I domain linker results in loss of ligand binding by abolishing the interdomain communication between the αL and β2 domains (33). The lack of dependence on Glu-310 in compound 4-induced αLβ2 activation suggests that compound 4 makes distinct contacts with the αL I domain or its linker that cause activation. However, at the same time, compound 4 (like other α/β allosteric antagonists) apparently blocks the Glu-310-β2 MIDAS interaction through competition for the binding to the MIDAS (37). Wild-type αLβ2 activated by compound 4 showed almost identical susceptibility to inhibitory antibodies as αL-E310C/β2-A210C, which is consistent with the notion that compound 4 induces interaction between the β2 I domain MIDAS and the C-terminal αL I domain linker similarly to the engineered disulfide bond in αL-E310C/β2-A210C.

The similarity between these activation mechanisms is further supported by our previous finding that αL-E310C/β2-A210C exhibits less binding to soluble multimeric ICAM-1 in Mn^{2+} than in Ca^{2+}/Mg^{2+} (33).

Our working model for agonism by compound 4 is as follows. Ca^{2+} and Mn^{2+} compete for binding to the Adjacent to MIDAS (ADMIDAS) metal ion binding site and by binding to this site inhibit and stimulate ligand binding, respectively, and coordinate with alternative ADMIDAS residues (48). In both Ca^{2+}/Mg^{2+} and Mn^{2+}, compounds 3–5 (XVA143) bind to the β2 MIDAS and block its interaction with αL-Glu-310. In Ca^{2+}/Mg^{2+}, the complex between compound 4 and the β2 I domain is slightly altered compared with its conformation in Mn^{2+} so that it is complementary to and can bind to the αL I domain or its linker and induce the open conformation of the αL I domain through interactions that do not involve, but functionally substitute for, the αL-Glu-310: β2-MIDAS interaction.
Despite agonistic stimulation of ligand binding, compound 4 can still block physiologic functions of αLβ2 that require cycles of adhesion and detachment. It has been proposed that integrins are active at the leading edge, whereas they are inactive at the trailing edge of migrating leukocytes (49, 50). Inactivation of integrins at the trailing edge is thought to be important for detaching the uropod (51). Indeed, sustained activation of α1 or α2 via activating antibodies (52, 53) or blockade of Rho signaling (54) suppressed eosinophil and monocyte transmigration by preventing the trailing edge from being detached.

We found that although compounds 4 and 5, BIRT377, and CBR LFA-1/2 all inhibit lymphocyte transmigration across the endothelium cell layer, they do so by different mechanisms. Compound 5 and BIRT377 distinctly promoted a predominant round cell population, with greatly reduced spreading and polarization consistent with a reduction in overall adhesiveness. In contrast, compound 4 and CBR LFA-1/2 Fab induced the migrating lymphocytes to display unusually long uropods that were highly enriched in αLβ2, consistent with increased adhesion and decreased de-adhesion in the trailing edge. This was confirmed by live-cell imaging analysis that demonstrated frustrated lateral migration induced by compound 4, in which failure of the uropod to detach limited lymphocyte migration. Thus, compound 5 (XVA143) blocks transendothelial migration by reducing adhesion, whereas compound 4 and CBR LFA-1/2 Fab block transendothelial migration by activating αLβ2 and interfering with uropod detachment. In a related finding, mutant mice expressing constitutively active αLβ2 were impaired in T cell migration, T cell proliferation stimulated by antigen presenting cells, cytotoxic T cell activity, T-dependent humoral immune responses, and neutrophil recruitment during aseptic peritonitis, although signaling through αLβ2 was not affected (31). The above observations are consistent with the previous report that compound 4 is a potent inhibitor of the mixed lymphocyte reaction (17). Our study demonstrates for the first time a small molecule integrin allosteric agonist that functions as an anti-inflammatory drug through a novel mechanism of action, perturbation of integrin de-adhesion.

Compound 4 is the first small molecule agonist reported for any integrin. Integrin agonists open up novel opportunities for therapeutics that increase rather than decrease integrin-dependent adhesion. For example, immune recognition of tumor cells is LFA-1-dependent, and agonists might enhance immune responses, including cytotoxic killing of tumor cells. Although we have found that agonism of αLβ2 decreases cell migration, and mice with permanently up-regulated αLβ2 are functionally impaired, appropriate dosing could allow cycles of agonism at peak drug levels to be alternated with cell migration during intervening troughs. There is extensive precedent with G-protein-coupled receptors for closely related compounds to act as agonists and antagonists (inverse agonists), and both types of compounds have important therapeutic applications.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**References**

1. Anderson, DC.; Smith, CW.; Springer, TA. Metabolic Basis of Inherited Disease. 6th Ed. Stanbury, JB.; Wyngaarden, JB.; Frederickson, DS., editors. McGraw-Hill; New York: 1989. p. 2751-2777.

2. Springer TA. Nature 1990;346:425–433. [PubMed: 1974032]

3. Harlan, JM.; Winn, RK.; Vedder, NB.; Doerschuk, CM.; Rice, CL. Adhesion: Its Role in Inflammatory Disease. Harlan, JR.; Liu, D., editors. W. H. Freeman and Co.; New York: 1992. p. 117-150.

4. Giblin PA, Kelly TA. Annu Rep Med Chem 2001;36:181–190.

5. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Med Res Rev 2002;22:146–167. [PubMed: 11857637]
6. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P, Bauer R, White M, Dedrick R, Garovoy M. J Am Acad Dermatol 2000;42:428–435. [PubMed: 10688712]

7. Gottlieb AB, Bos JD. Clin Immunol 2002;105:105–116. [PubMed: 12482385]

8. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Arch Dermatol 2002;138:591–600. [PubMed: 12020219]

9. Cather JC, Menter A. Expert Opin Biol Ther 2003;3:361–370. [PubMed: 12662148]

10. Lebwohl M, Terying SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D. N Engl J Med 2003;349:2004–2013. [PubMed: 14627785]

11. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. Nat Med 2001;7:687–692. [PubMed: 11385505]

12. Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki R, Legge G, Cottens S, Weitz-Schmidt G, Hommel U. J Mol Biol 1999;292:1–9. [PubMed: 10493852]

13. Last-Barney K, Davidson W, Cardozo M, Frye LL, Grygon CA, Hopkins JL, Jeanfavre DD, Pav S, Qian C, Stevenson JM, Tong L, Zindell R, Kelly TA. J Am Chem Soc 2001;123:5643–5650. [PubMed: 11403595]

14. Liu G, Huth JR, Olejniczak ET, Mendoza R, DeVries P, Lelita EB, Okasinski GF, Fesik SW, von Geldern TW. J Med Chem 2001;44:1202–1210. [PubMed: 11312920]

15. Burdick, D. J. (March 24, 1999) International Patent WO9949856

16. Burdick, D. J., Gadek, T. R., Marsters, J., Oare, D. A., Reynolds, M. E., and Stanley, M. S. (November 26, 2001) International Patent WO02059114

17. Gadek TR, Burdick DJ, McDowell RS, Stanley MS, Marsters JC Jr, Paris KJ, Oare DA, Reynolds ME, Ladner C, Zioncheck KA, Lee WP, Gripling P, Dennis MS, Skelton NJ, Tumas DB, Clark KR, Keating SM, Beresini MH, Tilley JW, Presta LG, Bodary SC. Science 2002;295:1086–1089. [PubMed: 11834839]

18. Humphries MJ, Biochem Soc Trans 2002;28:311–339. [PubMed: 10961914]

19. Gahnberg CG, Tolvanen M, Kotovuori P. Eur J Biochem 1997;245:215–232. [PubMed: 9151947]

20. Shimaoka M, Takagi J, Springer TA. Annu Rev Biophys Biomol Struct 2002;31:485–516. [PubMed: 11988479]

21. Lee JO, Rieu P, Arnauot MA, Liddington R. Cell 1995;80:631–638. [PubMed: 7867070]

22. Huang C, Zang Q, Takagi J, Springer TA. J Biol Chem 2000;275:21514–21524. [PubMed: 10779511]

23. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL, Arnaout MA. Science 2001;294:339–345. [PubMed: 11546839]

24. Song G, Yang Y, Liu J-h, Casasnovas J, Shimaoka M, Springer TA, Wang J-h. Proc Natl Acad Sci U S A 2005;102:3366–3371. [PubMed: 15728350]

25. Shimaoka M, Shifman JM, Jing H, Takagi J, Mayo SL, Springer TA. Nat Struct Biol 2000;7:674–678. [PubMed: 10932253]

26. Shimaoka M, Lu C, Palframan R, von Andrian UH, Takagi J, Springer TA. Proc Natl Acad Sci U S A 2001;98:6009–6014. [PubMed: 11353828]

27. Takagi J, Petre BM, Walz T, Springer TA. Cell 2002;110:599–611. [PubMed: 12230977]

28. Luo BH, Takagi J, Springer TA. J Biol Chem 2004;279:10215–10221. [PubMed: 14681220]

29. Yang W, Shimaoka M, Chen JF, Springer TA. Proc Natl Acad Sci U S A 2004;101:2333–2338. [PubMed: 14983010]

30. Xiao T, Takagi J, Wang J-h, Coller BS, Springer TA. Nature 2004;432:59–67. [PubMed: 15378069]

31. Semmrich M, Smith A, Feterowski C, Beer S, Engelhardt B, Busch DH, Bartsch B, Laschinger M, Hogg N, Pfeffer K, Holzmann B. J Exp Med 2005;201:1987–1998. [PubMed: 15958366]

32. Alonso JL, Essafi M, Xiong JP, Stehle T, Arnaout MA. Curr Biol 2002;12:340–342.

33. Yang W, Shimaoka M, Salas A, Takagi J, Springer TA. Proc Natl Acad Sci U S A 2004;101:2906–2911. [PubMed: 14978279]

34. Lu C, Shimaoka M, Zang Q, Takagi J, Springer TA. Proc Natl Acad Sci U S A 2001;98:2393–2398. [PubMed: 11226250]

J Biol Chem. Author manuscript; available in PMC 2007 January 9.
35. Fotouhi, N., Gillespie, P., Guthrie, R., Pietranico-Cole, S., and Yun, W. (October 12, 1999) International Patent WO0021920
36. Welzenbach K, Hommel U, Weitz-Schmidt G. J Biol Chem 2002;277:10590–10598. [PubMed: 11781316]
37. Shimaoka M, Salas A, Yang W, Weitz-Schmidt G, Springer TA. Immunity 2003;19:391–402. [PubMed: 14499114]
38. Dransfield I, Hogg N. EMBO J 1989;8:3759–3765. [PubMed: 2479549]
39. Robinson MK, Andrew D, Rosen H, Brown D, Ortlepp S, Stephens P, Butcher EC. J Immunol 1992;148:1080–1085. [PubMed: 1371129]
40. Lu C, Springer TA. J Immunol 1997;159:268–278. [PubMed: 9200463]
41. Carman CV, Springer TA. J Cell Biol 2004;167:377–388. [PubMed: 15504916]
42. Salas A, Shimaoka M, Kogan AN, Harwood C, von Andrian UH, Springer TA. Immunity 2004;20:393–406. [PubMed: 15084269]
43. Kim M, Carman CV, Springer TA. Science 2003;301:1720–1725. [PubMed: 14500982]
44. Huth JR, Olejniczak ET, Mendoza R, Liang H, Harris EA, Lupher ML Jr, Wilson AE, Fesik SW, Staunton DE. Proc Natl Acad Sci U S A 2000;97:5231–5236. [PubMed: 10805782]
45. Lu C, Shimaoka M, Ferzly M, Oxvig C, Takagi J, Springer TA. Proc Natl Acad Sci U S A 2001;98:2387–2392. [PubMed: 11226249]
46. Lu C, Shimaoka M, Salas A, Springer TA. J Immunol 2004;173:3972–3978. [PubMed: 15356146]
47. Keating SM, Clark KR, Stefanich LD, Arellano F, Edwards CP, Bodary SC, Spencer SA, Gadek TR, Marsters JC Jr, Beresini MH. Protein Sci 2006;15:290–303. [PubMed: 16384997]
48. Chen JF, Salas A, Springer TA. Nat Struct Biol 2003;10:995–1001. [PubMed: 14608374]
49. Springer, TA.; Anderson, DC. Ciba Symposium. 118. Pitman; London: 1986. Biochemistry of Macrophages; p. 102-126.
50. Smith A, Bracke M, Leitinger B, Porter JC, Hogg N. J Cell Sci 2003;116:3123–3133. [PubMed: 12799414]
51. Sanchez-Madrid F, del Pozo MA. EMBO J 1999;18:501–511. [PubMed: 9927410]
52. Kuipers TW, Mul EPJ, Blom M, Kovach NL, Gaeta FCA, Tollefson V, Elices MJ, Harlan JM. J Exp Med 1993;178:279–284. [PubMed: 7686213]
53. Weber C, Lu CF, Casasnovas JM, Springer TA. J Immunol 1997;159:3968–3975. [PubMed: 9378985]
54. Worthylake RA, Lemoine S, Watson JM, Burridge K. J Cell Biol 2001;154:147–160. [PubMed: 11448997]
FIGURE 1. Mechanisms of inhibition and chemical structures of α/βI allosteric antagonists
A, mechanisms of inhibition and impact on integrin conformation of α/βI allosteric antagonists. α/βI allosteric inhibitors bind to the β₂ I domain MIDAS near a key regulatory interface with the α₄ I domain and block communication of conformational change to the I domain while at the same time activating conformational rearrangements elsewhere in integrins, including swing-out of the hybrid domain. B, chemical structures of α/βI allosteric antagonists.
FIGURE 2. Compound 4 inhibits $\alpha_4\beta_2$ in Mn$^{2+}$ but activates $\alpha_4\beta_2$ in Ca$^{2+}$ and Mg$^{2+}$

A–C, soluble multimeric ICAM-1 binding by K562 stable transfectants expressing wild-type $\alpha_4\beta_2$. Cells were incubated with compounds in Hepes, NaCl, glucose, bovine serum albumin supplemented with 1 mM CaCl$_2$ and 1 mM MgCl$_2$ (A), 2 mM MnCl$_2$ (B), or 1 mM CaCl$_2$, 1 mM MgCl$_2$, and 10 $\mu$g/ml CBR LFA-1/2 (C) for 30 min at room temperature. Then fluorescein isothiocyanate-labeled multimeric ICAM-1 was added and incubated with cells for another 30 min at room temperature. The binding was detected by flow cytometry and is expressed as mean fluorescence intensity (MFI).

D, soluble multimeric ICAM-1 binding by human PBMCs. Binding was assayed as in A–C with cations, compounds (1 $\mu$M), and TS2/14 mAb (10 $\mu$g/ml) as indicated.

E, static adhesion of $\alpha_4\beta_2$-expressing K562 cells to immobilized ICAM-1 was as described in “Experimental Procedures” with cations and compounds (1 $\mu$M) as indicated.

F, adhesion in shear flow of $\alpha_4\beta_2$-expressing K562 cells to immobilized ICAM-1. K562 cells expressing wild-type $\alpha_4\beta_2$ were incubated in media containing different divalent cations and compounds (1 $\mu$M) as above. Cells were allowed to accumulate on an ICAM-1-Fc-coated substrate at 0.3 dyn/cm$^2$ in the flow chamber for 30 s before increasing the flow rate every 10 s in about 2-fold increments to the indicated wall shear stresses. Bars show the total number of adherent cells, including cells that were rolling (white) or firmly adherent (black).
FIGURE 3. Inhibition of agonism by compound 4 with compound 5 and LFA703
Soluble, multimeric ICAM-1 binding by αLβ2-expressing K562 cells was determined as described in Fig. 2A in 1 mM CaCl₂, 1 mM MgCl₂ after co-incubation with the indicated concentrations of compound 4 and compound 5 (A) or LFA703 (B).
FIGURE 4. Compound 4 and Mn$^{2+}$ activate $\alpha_L\beta_2$ by different mechanisms
Soluble ICAM-1 binding by K562 transfectants expressing wild-type or mutant $\alpha_L\beta_2$ was as described in Fig. 2A in the presence of cations and compounds (1 μM) as indicated. MFI, mean fluorescence intensity.
FIGURE 5. Effect of compounds on the conformation of $\alpha_L\beta_2$

$A$ and $B$, effect of compounds on expression of activation epitopes on $\alpha_L\beta_2$. $\alpha_L\beta_2$-Expressing K562 cells were stained with m24 ($A$) or KIM127 ($B$) in Hepes buffer containing 1 mM CaCl$_2$, 1 mM MgCl$_2$ and compounds at 37 $^\circ$C for 30 min followed by immunofluorescence flow cytometry. $C$, binding of compounds induces spatial separation of $\alpha_L\beta_2$ cytoplasmic domains. FRET was measured in $\alpha_L$-mCFP/$\beta_2$-mYFP K562 transfectants after treatment with compounds (1 $\mu$M) or 1 mM Mn$^{2+}$ and soluble monomeric ICAM-1 (slICAM-1) 100 $\mu$g/ml as indicated. Data are the mean ± S.E. for 8 to 10 cells. *, $p < 0.05$ versus control. MFI, mean fluorescence intensity.
FIGURE 6. Effect of compounds on lymphocyte diapedesis
Interleukin-2-cultured human lymphocytes were incubated with TNF-α-activated HUVEC monolayers for 10 or 60 min (A) or 10 min (B–D) in the absence or presence of compounds or CBR LFA-1/2 Fab, fixed, and stained as described under “Experimental Procedures.” For each experiment a minimum of 100 lymphocytes from randomly selected fields were carefully analyzed to determine stage of diapedesis and morphology as described under “Experimental Procedures.” A, quantitation of transendothelial migration (TEM). The number of cells having either initiated or completed diapedesis is expressed as a percentage of total cells. Values represent mean ± S.E. of 3–6 independent experiments. DMSO, dimethyl sulfoxide. B–D, morphologic characterization of lymphocytes. Lymphocytes and HUVECs were fixed and stained for αL integrin (green) and F-actin (red). Representative micrographs demonstrate each of four principal morphologic categories (round, spread, polarized, and X-polarized) observed among the apically adherent cells. C, the number of cells displaying each of the morphologies is expressed as a percentage of the total. Values represent mean ± S.E. of 3–8 experiments. D, representative fields used for the quantitation shown in C.
FIGURE 7. Dynamics of lymphocyte lateral migration and diapedesis across endothelium
Live-cell imaging and analysis of lymphocytes migrating on TNF-α-activated HUVEC monolayers was as described under “Experimental Procedures.” For each condition, greater than 50 cells, taken from four separate imaging experiments (see representative experiments in supplemental Videos 1 and 2) were analyzed. A and B, two-dimensional tracks of lymphocytes migrating over a 30-min period under control conditions (A) and in the presence of 1 μM compound 4 (B). Tracks of cells that initiated diapedesis during the imaging time course are terminated at the point of initiation of diapedesis and are depicted in red. C–E, kinetics of migration of representative lymphocytes. C–D, left panels are selected frames from representative live-cell imaging experiments under control condition (C, see Video 1) and in the presence of compound 4 (D, see Video 2). Representative cells (boxed region in left panels) were tracked at 50-s intervals. The outline (red) of the cell position at relative time 0 is shown in all panels. Note that in control condition (C) the migrating cell steadily increases its distance from its origin over time, whereas in the presence of compound 4 (D) the cell repeatedly moves away from and then contracts back toward the origin. E, the distances from the origin of the centroids of the two migrating cells shown in C and D are plotted against time for control (black) and compound 4 (red) conditions. The control cell is only tracked for 7 min because after this it left the boxed region in Fig. 7C.
TABLE 1

Inhibition by αL I and β2 I domain antibodies of multimeric ICAM-1 binding to αLβ2 mutants

Wild-type (WT) αLβ2 in K562 transfectants was activated by preincubation with 10 μg/ml mAb CBR LFA-1/2 (WT + mAb) or 1 μM compound 4 (WT + #4). CC, αL-E310C/β2-A210C. HA, αLβ2 with the high affinity K287C/K294C I domain mutation. Binding to soluble, multimeric ICAM-1 in medium containing 1 mM CaCl₂ and 1 mM MgCl₂ was in the presence of the indicated mAb. All mAbs bound to αL-E310C/β2-A210C, K287C/K294C, and wild-type αLβ2 with or without compound 4 equally well (data not shown).

| mAb     | Domain | Epitope               | Inhibition |          |          |
|---------|--------|-----------------------|------------|----------|----------|
|         |        |                       |            | WT µmAb  | CC       | WT #4    | HA       |
| TS2/6   | αL I   | 154–183               |            | 97       | 96       | 99       | 97       |
| May.035 | αL I   | Lys-197, His-201      |            | 98       | 98       | 99       | 97       |
| MHM24   | αL I   | Lys-197               |            | 96       | 97       | 98       | 96       |
| TS1/22  | αL I   | Gln-266, Ser-270      |            | 96       | 97       | 96       | 92       |
| TS2/14  | αL I   | Ser-270, Glu-272      |            | 99       | 99       | 99       | 14       |
| May.017 | β2 I   | Glu-175, ?            |            | 98       | 70       | 82       | 3        |
| MHM23   | β2 I   | Glu-175               |            | 97       | 40       | 12       | 2        |
| TS1/18  | β2 I   | Arg-133, His-332      |            | 98       | 4        | 0        | 0        |
| YFC51   | β2 I   | Arg-133, His-332      |            | 98       | 2        | 0        | 0        |
| CLB LFA-1/1 | β2 I | His-332, Asn-339 |            | 97       | 2        | 0        | 0        |